Na Jian-Rong, Liu Yaqin, Fang Kun, Tan Yuan, Liang Pan-Pan, Yan Mei, Chu Jiao-Jiao, Gao Jian-Mei, Chen Dongsheng, Zhang Shu-Xiang
Department of Respiratory and Critical Care Medicine, the First Clinical College of Ningxia Medical University, Yinchuan, 750004, China.
The State Key Laboratory of Neurology and Oncology Drug Development, Jiangsu Simcere Diagnostics Co., Ltd, Nanjing Simcere Medical Laboratory Science Co., Ltd, Nanjing, 210002, China.
Invest New Drugs. 2024 Dec;42(6):728-738. doi: 10.1007/s10637-024-01478-4. Epub 2024 Oct 21.
The ongoing research on the role of immunotherapy in advanced ovarian cancer (OC) and current clinical trials indicate that patients shown limited response to immune checkpoint inhibitor (ICI) monotherapy. When combined with other treatments or drugs, the efficacy of immunotherapy will be significantly improved. Biomarkers can be used to identify patients with better responses, thereby improving the precision and efficacy of immunotherapy. Key biomarkers for advanced OC include homologous repair deficiency, programmed death-ligand (PD-L) 1 expression, chemokines, and tumor infiltrating lymphocytes. These biomarkers could be applied in the future to select the most suitable patient populations. This review comprehensively examines the research and development of biomarkers in OC immunotherapy from three omics perspectives: genomics, transcriptomics, and proteomics, which may provide guidance for the effectiveness of OC immunotherapy strategies.
正在进行的关于免疫疗法在晚期卵巢癌（OC）中作用的研究以及当前的临床试验表明，患者对免疫检查点抑制剂（ICI）单药治疗的反应有限。当与其他治疗方法或药物联合使用时，免疫疗法的疗效将显著提高。生物标志物可用于识别反应较好的患者，从而提高免疫疗法的精准性和疗效。晚期OC的关键生物标志物包括同源修复缺陷、程序性死亡配体（PD-L）1表达、趋化因子和肿瘤浸润淋巴细胞。这些生物标志物未来可用于选择最合适的患者群体。本综述从基因组学、转录组学和蛋白质组学这三个组学角度全面审视了OC免疫疗法中生物标志物的研发情况，这可能为OC免疫治疗策略的有效性提供指导。
